Demystifying Clinical Trials & Approval Processes
In Hot Copper’s recent webinar “Demystifying clinical trials and approval processes for ASX-listed companies”, CEO Dr Daniel Tillett spoke with Sonia Madigan to discuss Race Oncology’s journey through the drug development process.
Dr Tillett shared insights into the company’s unique market position and potential growth opportunities with lead drug, bisantrene.
You can watch Daniel’s interview as part of the webinar here.
